# US 2010/0143354 A1 · Triazine dna modifiers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143354 A1
- Document ID: US20100143354A1
- Status: Published application
- Kind: A1
- Application number: 12/630,897
- Filed: 2009-12-04
- Published: 2010-06-10
- Earliest claimed: 2008-12-04
- Assignees: Auspex Pharmaceuticals, Inc.
- Inventors: Thomas G. Gant; Sepehr Sarshar
- Web page: https://patentgrep.com/patent/US20100143354A1

## CPC

- C07D 251/70: Other substituted melamines
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new triazine DNA modifiers, pharmaceutical compositions thereof, and methods of use thereof

## Claims

### Claim 1

A compound of structural Formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1-R18 are independently selected from the group consisting of hydrogen and deuterium;
at least one of R1-R18 is deuterium;
if R1-R3, are deuterium, then at least one of R4-R18 is deuterium;
if R1-R3, R7-R9, and R13-R15 are deuterium, then at least one of R4-R6, and R16-R18 is deuterium; and
R1-R18 are not all deuterium.

### Claim 2 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R18 independently has deuterium enrichment of no less than about 10%.

### Claim 3 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R18 independently has deuterium enrichment of no less than about 50%.

### Claim 4 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R18 independently has deuterium enrichment of no less than about 90%.

### Claim 5 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R18 independently has deuterium enrichment of no less than about 98%.

### Claim 6 (depends on 1)

The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of

### Claim 7 (depends on 6)

The compound as recited in claim 6 wherein each position represented as D has deuterium enrichment of no less than about 10%.

### Claim 8 (depends on 6)

The compound as recited in claim 6 wherein each position represented as D has deuterium enrichment of no less than about 50%.

### Claim 9 (depends on 6)

The compound as recited in claim 6 wherein each position represented as D has deuterium enrichment of no less than about 90%.

### Claim 10 (depends on 6)

The compound as recited in claim 6 wherein each position represented as D has deuterium enrichment of no less than about 98%.

### Claim 11 (depends on 6)

The compound as recited in claim 6 wherein said compound has a structural formula selected from the group consisting of

### Claim 12 (depends on 6)

The compound as recited in claim 6 wherein said compound has a structural formula selected from the group consisting of

### Claim 13

A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a compound of structural Formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1-R18 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R18 is deuterium.

### Claim 14

A method of treatment of a neoplastic mediated-disorder comprising the administration, to a patient in need thereof, of a therapeutically effective amount of a compound of structural Formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1-R18 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R18 is deuterium.

### Claim 15 (depends on 14)

The method as recited in claim 14 wherein said disorder is selected from the group consiting of cancer and non-malignant neoplasms.

### Claim 16 (depends on 15)

The method as recited in claim 15 wherein said cancer is selected from the group consiting of cervical cancer, lung cancer, ovarian cancer, and small cell lung cancer.

### Claim 17 (depends on 14)

The method as recited in claim 14 further comprising the administration of an additional therapeutic agent.

### Claim 18 (depends on 17)

The method as recited in claim 17 wherein said additional therapeutic agent is selected from the group consisting of alkylating agents, anti-metabolite agents, mitotic inhibitors, tyrosine kinase inhibitors, topoisomerase inhibitors, cancer immunotherapy monoclonal antibodies, anti-tumor antibiotic agents, and anti-cancer agents.

### Claim 19 (depends on 18)

The method as recited in claim 18 wherein said alkylating agent is selected from the group consisting of chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.

### Claim 20 (depends on 18)

The method as recited in claim 18 wherein said anti-metabolite agent is selected from the group consisting of aminopterin, trimetrexate, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, tioguanine, cytarabine, fluorouracil, floxuridine, tegafur, carmofur, capecitabine and gemcitabine.

### Claim 21 (depends on 18)

The method as recited in claim 18 wherein said mitotic inhibitor is selected from the group consisting of docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.

### Claim 22 (depends on 18)

The method as recited in claim 18 wherein said tyrosine kinase inhibitor is selected from the group consisting of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib, and sunitinib.

### Claim 23 (depends on 18)

The method as recited in claim 18 wherein said topoisomerase inhibitor is selected from the group consisting of etoposide, etoposide phosphate, teniposide, camptothecin, topotecan, and irinotecan.

### Claim 24 (depends on 18)

The method as recited in claim 18 wherein said cancer immunotherapy monoclonal antibody is selected from the group consisting of rituximab, alemtuzumab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, and trastuzumab.

### Claim 25 (depends on 18)

The method as recited in claim 18 wherein said anti-tumor antibiotic agent is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea.

### Claim 26 (depends on 18)

The method as recited in claim 18 wherein said anti-cancer agent is selected from the group consisting of amsacrine, asparaginase, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, imatinib, denileukin diftitox, bortezomib, celecoxib, and anagrelide.

### Claim 27 (depends on 14)

The method as recited in claim 14, further resulting in at least one effect selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 28 (depends on 14)

The method as recited in claim 14, further resulting in at least two effects selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 29 (depends on 14)

The method as recited in claim 14, wherein the method effects a decreased metabolism of the compound per dosage unit thereof by at least one polymorphically-expressed cytochrome P450 isoform in the subject, as compared to the corresponding non-isotopically enriched compound.

### Claim 30 (depends on 29)

The method as recited in claim 29, wherein the cytochrome P450 isoform is selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and CYP2D6.

### Claim 31 (depends on 14)

The method as recited claim 14, wherein said compound is characterized by decreased inhibition of at least one cytochrome P450 or monoamine oxidase isoform in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 32 (depends on 31)

The method as recited in claim 31, wherein said cytochrome P450 or monoamine oxidase isoform is selected from the group consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4X1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, CYP51, MAOA, and MAOB.

### Claim 33 (depends on 14)

The method as recited in claim 14, wherein the method reduces a deleterious change in a diagnostic hepatobiliary function endpoint, as compared to the corresponding non-isotopically enriched compound.

### Claim 34 (depends on 33)

The method as recited in claim 33, wherein the diagnostic hepatobiliary function endpoint is selected from the group consisting of alanine aminotransferase (“ALT”), serum glutamic-pyruvic transaminase (“SGPT”), aspartate aminotransferase (“AST,” “SGOT”), ALT/AST ratios, serum aldolase, alkaline phosphatase (“ALP”), ammonia levels, bilirubin, gamma-glutamyl transpeptidase (“GGTP,” “γ-GTP,” “GGT”), leucine aminopeptidase (“LAP”), liver biopsy, liver ultrasonography, liver nuclear scan, 5′-nucleotidase, and blood protein.

### Claim 35

A compound, for use as a medicament, having structural Formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1-R18 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R18 is deuterium.

### Claim 36

A compound for use in the manufacture of a medicament for the prevention or treatment of a disorder ameliorated by the modification of DNA, said compound having structural Formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1-R18 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R18 is deuterium.
